News | Image Guided Radiation Therapy (IGRT) | June 14, 2018

Next-generation cancer therapy enables delivery of higher, potentially more effective radiation dose regimens

Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac

June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis has begun treating patients with Viewray's second-generation magnetic resonance (MR) image-guided radiotherapy system, the MRIdian Linac. Siteman is the first U.S. cancer center to offer cancer therapy with both MRIdian and MRIdian Linac.

Washington University physicians and researchers at Siteman played an integral role in the development, testing and clinical introduction of MRIdian in 2012. The first cancer patients worldwide to receive MR-guided radiation therapy were treated at Siteman.

Unlike conventional radiotherapy, MRIdian Linac technology uses high-definition MR soft-tissue imaging to visualize and track the detailed contours of the tumor and adjacent healthy tissues. The enhanced visibility allows clinicians to quickly and dynamically adjust the prescribed radiation dose distribution when the tumor moves during the course of treatment. The combined capabilities provide clinicians with the tools to improve targeting precision and thus deliver higher and potentially more effective radiation doses, while simultaneously minimizing incidental radiation exposure to surrounding organs.

"We know that tumors and their surrounding anatomy naturally change position from day to day — even during treatment — making it vitally important that we see where the radiation dose is being delivered in real-time," said Jeff Bradley, M.D., the S. Lee Kling Professor of Radiation Oncology at Washington University. "The clarity and detail afforded by MRI combined with this new technology allows us to target tumors with a high level of accuracy regardless of changes or motion, further enabling us to expand our treatment options."

"As an institution actively involved in advancing MR image-guided therapy since the very beginning, we are excited to remain at the forefront with the addition of this latest innovation," said Jeff Michalski, M.D., professor and vice chair of the Department of Radiation Oncology at Washington University.

For more information: www.viewray.com


Related Content

News | Stroke

Dec. 12, 2025 — Hyperfine, Inc. has announced that it has received FDA clearance for a new multi-direction diffusion ...

Time December 15, 2025
arrow
News | Radiopharmaceuticals and Tracers

Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens ...

Time December 11, 2025
arrow
News | Artificial Intelligence

Dec. 1, 2025 — Researchers at the University of California, Berkeley and University of California, San Francisco have ...

Time December 10, 2025
arrow
Feature | Uzay Emir and Stephen Sawiak

Healthcare has reached a critical juncture. The World Economic Forum estimates that global medical costs will see double ...

Time December 04, 2025
arrow
News | Interventional Radiology

Dec. 1, 2025 — GE HealthCare has unveiled the Allia Moveo,1 an image guiding solution designed to enhance mobility and ...

Time December 02, 2025
arrow
News | Advanced Visualization

Nov. 20, 2025 — Avatar Medical and Barco have launched Eonis Vision, marking a new evolution in how medical imaging is ...

Time November 20, 2025
arrow
News | Neuro Imaging

Nov. 19, 2025 — Royal Philips has announced an extended partnership with Cortechs.ai. Together, the companies will ...

Time November 19, 2025
arrow
Feature | Teleradiology | Kyle Hardner

Once viewed as a solution for after-hours coverage, teleradiology is rapidly expanding into a critical part of radiology ...

Time November 06, 2025
arrow
News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
Subscribe Now